Cone-Beam Computed Tomography-Derived Augmented Fluoroscopy Improves the Diagnostic Yield of Endobronchial Ultrasound-Guided Transbronchial Biopsy for Peripheral Pulmonary Lesions

Ching-Kai Lin 1,2,3, Hung-Jen Fan 1,4, Zong-Han Yao 1,2, Yen-Ting Lin 1,2, Yueh-Feng Wen 2,3, Shang-Gin Wu 1,2* and Chao-Chi Ho 2,4*

1 Department of Medicine, National Taiwan University Cancer Center, Taipei 106, Taiwan; vanhalen19781205@gmail.com (C.-K.L.); fnest.tw@gmail.com (H.-J.F.); med92leoyau@gmail.com (Z.-H.Y.); shwansiformosa@gmail.com (Y.-T.L.); b8501091@gmail.com (S.-G.W.)
2 Department of Internal Medicine, National Taiwan University Hospital, Taipei 100, Taiwan; freeman0509@gmail.com
3 Department of Internal Medicine, National Taiwan University Hsin-Chu Hospital, Hsin-Chu 300, Taiwan
4 Department of Internal Medicine, National Taiwan University Biomedical Park Hospital, Hsin-Chu County 310, Taiwan
* Correspondence: ccho1203@ntu.edu.tw; Tel.: +886-22356-2905

Abstract: Background: Endobronchial ultrasound-guided transbronchial biopsy (EBUS-TBB) is used for the diagnosis of peripheral pulmonary lesions (PPLs), but the diagnostic yield is not adequate. Cone-beam computed tomography-derived augmented fluoroscopy (CBCT-AF) can be utilized to assess the location of PPLs and biopsy devices, and has the potential to improve the diagnostic accuracy of bronchoscopic techniques. The purpose of this study was to verify the contribution of CBCT-AF to EBUS-TBB. Methods: Patients who underwent EBUS-TBB for diagnosis of PPLs were enrolled. The navigation success rate and diagnostic yield were used to evaluate the effectiveness of CBCT-AF in EBUS-TBB. Results: In this study, 236 patients who underwent EBUS-TBB for PPL diagnosis were enrolled. One hundred fifteen patients were in CBCT-AF group and 121 were in non-AF group. The navigation success rate was significantly higher in the CBCT-AF group (96.5% vs. 86.8%, \( p = 0.006 \)). The diagnostic yield was even better in the CBCT-AF group when the target lesion was small in size (68.8% vs. 0%, \( p = 0.026 \) for lesions \( \leq 10 \) mm and 77.5% vs. 46.4%, \( p = 0.016 \) for lesions 10–20 mm, respectively). The diagnostic yield of the two study groups became similar when the procedures with a failure of navigation were excluded. The procedure-related complication rate was similar between the two study groups. Conclusion: CBCT-AF is safe, and effectively enhances the navigation success rate, thereby increasing the diagnostic yield of EBUS-TBB for PPLs.

Keywords: cone-beam computed tomography-derived augmented fluoroscopy; diagnostic yield; endobronchial ultrasound-guided transbronchial biopsy; navigation success rate; peripheral pulmonary lesion
EBUS-TBB alone has ranged from 60–70% [6–8]. Combined use with other methods, such as fluoroscopy or virtual bronchoscopic navigation, has been attempted to improve diagnostic accuracy [9–11]. However, these techniques have their limitations or disadvantages, so a more effective system is required to assist EBUS-TBB procedures.

Cone-beam CT (CBCT) is a newer CT modality that can provide both real-time 2-dimensional (2D) fluoroscopy and 3D CBCT scans. With dedicated software, the target can be contoured, and be projected onto live fluoroscopy images, termed augmented fluoroscopy (AF). This system provides real-time information for interventional radiologists and surgeons in many advanced procedures [12–17]. However, there is scant evidence as to the utility of combining EBUS-TBB and CBCT-derived AF (CBCT-AF) in the diagnosis of PPLs. Our aims in this study were to investigate the effectiveness of CBCT-AF in EBUS-TBB, and to evaluate the possible reason for CBCT-AF’s effect on the diagnostic yield.

2. Materials and Methods

2.1. Participants

This was a retrospective chart review of patients who underwent EBUS-TBB for PPL diagnosis at the Department of Thoracic Medicine, National Taiwan University Cancer Center and National Taiwan University Hsin-Chu Hospital, from January 2018 to June 2020. Each patient underwent an EBUS-TBB procedure once, and only one target lesion was sampled in each procedure.

Patient data regarding age, gender, and final diagnosis were collected. In order to characterize the EBUS-TBB procedure, the following data were also recorded: the indication (initial diagnosis vs. re-biopsy), lesion size (length of the long axis measured on the CT image), lesion pattern (solid vs. part-solid/ground glass opacity (GGO) on the CT image), presence or absence of a bronchus sign, lesion location, visibility of the lesions on chest plain film, guide sheath use, location of the probe (within vs. adjacent to/invisible), procedure time (interval between insertion and removal of the bronchoscope through the vocal cords), procedure-related major adverse events, and radiation dose.

The study population was divided into two groups depending on the use of CBCT-AF. We defined the “CBCT-AF group” as those that underwent CBCT-AF combined with EBUS-TBB. The “non-AF group” included those for whom CBCT-AF was not performed during the EBUS-TBB procedure. Written informed consent was obtained from each patient prior to bronchoscopy. The study was approved by the National Taiwan University Cancer Center Institutional Review Board in 8 April 2021 (IRB # 202102061RINC).

2.2. Procedures

All bronchoscopy procedures were performed by our pulmonologist (C.K.L.), who had more than 10 years of experience in EBUS-TBB. All EBUS-TBB procedures in the non-AF group were performed at National Taiwan University Hsin-Chu Hospital, depending on the general bronchoscopy room setting. All CBCT-AF procedures, with or without intra-procedural CBCT procedures (CBCT-AF group), were performed in the hybrid bronchoscopy room with a C-arm CBCT angiography system (Artis Zee Ceiling; Siemens Healthcare GmbH, Forchheim, Germany) at National Taiwan University Cancer Center.

Each patient in the CBCT-AF group was placed on the angiographic table in the supine position before EBUS-TBB. To acquire the 3D dataset, the C-arm needed to rotate 200° (180° plus the fan angle) around the target, maintaining an inspiratory hold. A radiological technician highlighted the area of the target lesion and target bronchus using annotation software (syngo iGuide Toolbox; Siemens Healthcare GmbH, Forchheim, Germany). The annotated marker was then projected onto the 2D-fluoroscopy live screen in accordance with the corresponding 3D locations; thus, the AF system was configured.

After premedication with lidocaine local anesthesia and intravenous midazolam/propiol and fentanyl for conscious sedation, all patients in both groups underwent the EBUS-TBB procedure using a flexible bronchoscope (BF-Q290 or BF-P290; Olympus Co., Tokyo, Japan) combined with a 20 MHz radial-EBUS (UM-S20-17S; Olympus Co., Tokyo, Japan). In the
non-AF group, the radial-EBUS was inserted through the working channel of the scope into the suspected target bronchus, based on CT findings and without a navigation system. In the CBCT-AF group, radial-EBUS was guided by AF imaging. After confirming the location of the lesion using radial-EBUS imaging (defined as “success of navigation”), with or without intraprocedural CBCT, TBB with forceps (NBF01-11018120; MICRO-TECH Co. Ltd., Nanjing, China) or a commercial GS kit (K201; Olympus Co., Tokyo, Japan) was carried out for specimen collection. Rapid on-site cytologic evaluation (ROSE) was always available for confirming lesion access. The material from the forceps biopsy was imprinted on a clear glass slide, and then stained using a rapid method (Hemacolor; Merck KGaA, Darmstadt, Germany) for ROSE. If neither a malignant cell nor a specific finding was noted by the ROSE study, we would change to another site for biopsy. The procedure would be terminated when there was no specific finding more than 3×, or if the patient could no longer tolerate the procedure. The histologic samples were placed in 10% formalin and were embedded in paraffin for routine histologic evaluation with hematoxylin and eosin staining, and were interpreted by our cytopathologists. Tissue cultures of bacteria, mycobacteria, and fungus would also be added when an infectious PPL was suspected. If radial-EBUS was unable to detect the target lesion, or radial-EBUS unable to arrive to the target lesion that confirmed by intraprocedural CBCT (meaning “navigation failure”), no further TBB would be performed. Neither brushing nor transbronchial needle aspiration was performed during the procedure. Figure 1 shows the flowchart of the procedure in CBCT-AF and non-AF groups, and Figure 2 shows imaging results for a lung cancer patient diagnosed by CBCT-AF and EBUS-TBB.

**Figure 1.** Flowchart of the procedure in CBCT-AF and non-AF groups. AF, augmented fluoroscopy; CBCT-AF, cone-beam computed tomography-derived augmented fluoroscopy; EBUS, endobronchial ultrasound; ROSE, rapid on-site cytologic evaluation; TBB, transbronchial biopsy.
2.3. Diagnosis

The final diagnosis of PPLs was established based on cytopathologic evidence, microbiological analyses, or clinical follow-up. Benign inflammation, which could not be determined cytopathologically or microbiologically, were confirmed by radiological and clinical follow-up (unchanged or decreased lesion size on the CT image) at least 6 months after bronchoscopy. Malignant PPLs underwent re-biopsy after cancer treatment, and malignancy with disease progression was still considered if the lesions were enlarged, as

Figure 2. A 75-year-old female patient received CBCT-AF combined with EBUS-TBB, and was finally diagnosed with lung adenocarcinoma. (A) standard CT image showing a small nodule (10.6 mm) at the left lower lobe; (B) the target lesion on CBCT image contoured in three standard axes for the AF image; (C,D) a concentric peribronchial lesion discovered by radial-EBUS via AF guidance; (E) TBB guided by AF image. AF, augmented fluoroscopy; CBCT-AF, cone-beam computed tomography-derived augmented fluoroscopy; CT, computed tomography; EBUS-TBB, endobronchial ultrasound-guided transbronchial biopsy; TBB, transbronchial biopsy.
seen in the radiological follow-up, and if an infection/inflammation process was excluded, even if there was no histological confirmation.

2.4. Statistical Analysis

We evaluated the effectiveness of CBCT-AF in EBUS-TBB based on the navigation success rate and diagnostic yield. The navigation success rate was defined as a “successful navigation class/total testing class”. The diagnostic yields were defined as “correctly TBB-proved class/total testing class”. For malignant PPLs, “correctly TBB-proved class” means that positive of cytologic or pathologic report revealed by TBB specimens. Suspicious findings were considered nondiagnostic in our study. For infectious PPLs, “correctly TBB-proved” needs positive tissue culture result via TBB specimen if no microorganism is detected from histologic report. The “correctly TBB-proved class” was also mean true positive. When “chronic inflammation” was revealed via histologic report, “true negative” would still be considered if no specific infection/inflammation process was found, and the PPLs decreased in size or disappeared within 6 months follow-up without any special treatment. False negatives were defined as TBB samples revealed negative malignant histologic report initially, and malignant cells discovered later through repeated biopsy via any biopsy methods, or disease progression confirmed via radiological and clinical follow-up. The sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and diagnostic accuracy were calculated via standard definitions.

Comparisons were made using Student’s t test or one-way analysis of variance (ANOVA) for continuous variables, and the \( \chi^2 \) test or Fisher’s exact test for categorical variables. A \( p \)-value of less than 0.05 was considered significant. We used SPSS version 21.0 (IBM, SPSS, Chicago, IL, USA) for statistical analysis.

3. Results
3.1. Patients and Target Lesions

In all, 236 patients who underwent 236 EBUS-TBB procedures for PPL diagnosis were enrolled during our study period. One hundred fifteen patients (procedures) were in CBCT-AF group and 121 patients (procedures) were in non-AF group. The mean age of our total study population was 66.1 years, and 50% of the patients were male. Malignant diagnoses were common (73.3%) in our study population, and most of them were primary lung cancer. The CBCT-AF group had a higher proportion of malignancy. The details of the final diagnoses of both groups and the corresponding cytopathologic results are shown in Tables 1 and 2.

In the present study, the lesion size was smaller in the CBCT-AF group (24.0 mm vs. 30.6 mm, \( p < 0.001 \)). The proportion of lesions with a solid appearance was lower in the CBCT-AF group than in the non-AF group (76.5% vs. 86.8%, \( p = 0.030 \)). Fewer patients in the CBCT-AF group used a guide sheath than in the non-AF group (39.1% vs. 65.3%, \( p < 0.001 \)). Longer procedure duration was also noted in the CBCT-AF group (41.9 min vs. 34.4 min, \( p < 0.001 \)). There were no statistically significant differences between the 2 groups in terms of the indication of the procedure, location of the target lesions, presence of a bronchus sign, location of the radial-EBUS probe, visibility of the lesions on chest plain film, and procedure-related complications. No serious respiratory or hemodynamic adverse event was documented (Table 3).
Table 1. Characteristics of the patients.

| Characteristics                        | Total (n = 236) | CBCT-AF (n = 115) | Non-AF (n = 121) | p-Value |
|----------------------------------------|-----------------|-------------------|------------------|---------|
| Age (years old, range)                 | 66.1 (28–94)    | 65.1 (28–91)      | 67.0 (31–94)     | 0.258   |
| Male gender (%)                        | 118 (50)        | 50 (43.5)         | 68 (56.2)        | 0.051   |
| Final diagnosis (%)                    |                 |                   |                  |         |
| Malignancy                             | 173 (73.3)      | 92 (80)           | 81 (66.9)        | 0.017 * |
| Lung adenocarcinoma                    | 145 (61.4)      | 73 (63.5)         | 72 (59.5)        |         |
| Lung squamous cell carcinoma           | 8 (3.4)         | 4 (3.5)           | 4 (3.3)          |         |
| Small cell lung cancer                 | 3 (1.3)         | 2 (1.7)           | 1 (0.8)          |         |
| Other NSCLC                            | 8 (3.4)         | 5 (4.3)           | 3 (2.5)          |         |
| Metastasis                             | 9 (3.8)         | 8 (7.0)           | 1 (0.8)          |         |
| Colorectal cancer                      | 2 (0.8)         | 2 (1.7)           | 0 (0)            |         |
| Breast cancer                          | 2 (0.8)         | 2 (1.7)           | 0 (0)            |         |
| Urothelial cancer                      | 2 (0.8)         | 2 (1.7)           | 0 (0)            |         |
| Melanoma                               | 1 (0.4)         | 1 (0.9)           | 0 (0)            |         |
| Multiple myeloma                       | 1 (0.4)         | 1 (0.9)           | 0 (0)            |         |
| Hepatocellular carcinoma               | 1 (0.4)         | 0 (0)             | 1 (0.8)          |         |
| Non-malignancy                         | 63 (26.7)       | 23 (20)           | 40 (33.1)        |         |
| Fungus                                 | 11 (4.7)        | 5 (4.3)           | 6 (5.0)          |         |
| Aspergillosis                          | 4 (1.7)         | 2 (1.7)           | 2 (1.7)          |         |
| Cryptococcus                           | 3 (1.3)         | 2 (1.7)           | 1 (0.8)          |         |
| Candida                                | 3 (1.3)         | 0 (0)             | 3 (2.5)          |         |
| Pneumocystis jirovecii pneumonia       | 1 (0.4)         | 1 (0.9)           | 0 (0)            |         |
| Mycobacterium tuberculosis            | 8 (3.4)         | 2 (1.7)           | 6 (5.0)          |         |
| Non-tuberculous Mycobacteria           | 2 (0.8)         | 2 (1.7)           | 0 (0)            |         |
| Pneumonia                              | 15 (6.4)        | 6 (5.2)           | 9 (7.4)          |         |
| Hamartoma                              | 1 (0.4)         | 0 (0)             | 1 (0.8)          |         |
| Benign inflammation                    | 25 (10.6)       | 8 (7.0)           | 18 (14.9)        |         |

AF = augmented fluoroscopy; CBCT-AF = cone beam computed tomography-derived augmented fluoroscopy; n = number; NSCLC = non-small cell lung cancer; * = statistical significance with p-value < 0.05.

In the CBCT-AF group, intra-procedural CBCT was more frequently used for smaller target lesions (≤10 mm vs. 10–20 mm vs. >20 mm, 37.5% vs. 25% vs. 5.1%, respectively). The mean radiation dose for fluoroscopy was 2.70 Gy·cm², and the Dyna-CT dose was 22.78 Gy·cm². The mean total radiation dose was 25.48 Gy·cm².

3.2. Navigation Success Rate and Diagnostic Yield

The CBCT-AF group had a higher navigation success rate than the non-AF group (96.5% vs. 86.8%, p = 0.006). In the subgroup analysis, the effect of CBCT-AF on the navigation success rate was significant in patients with a small lesion size (CBCT-AF vs. non-AF: 87.5% vs. 0%, p = 0.003 in the subgroup with lesions ≤ 10 mm, and 95% vs. 71.4%, p = 0.009 in the subgroup with lesions 10–20 mm in size, respectively) (Table 4).

Smaller lesions also had a higher diagnostic yield in the CBCT-AF group. When the lesion size was ≤10 mm, the diagnostic yield was 68.8% (11/16) in the CBCT-AF group, and no patient (0/4) with a lesion that size was successfully diagnosed in the non-AF group (p = 0.026). The diagnostic yield of EBUS-TBB for lesions 10–20 mm in size in the non-AF group was only 46.4% (13/28). The diagnostic yield was significantly elevated to 77.5% (31/40) when CBCT-AF was performed with EBUS-TBB (p = 0.016) (Table 4). The performance of the diagnosis of PPLs between CBCT-AF and non-AF groups were in Table 5.
| Cytopathologic Finding of TBB | CBCT-AF (n = 115) | Non-AF (n = 121) |
|-------------------------------|------------------|------------------|
|                              | n | Details of Final Diagnosis   | n | Details of Final Diagnosis   |
| TBB diagnostic                |   |                              | 90 |                              |
| Malignant                     | 76 |                              | 58 |                              |
| Lung adenocarcinoma           | 60 |                              | 51 |                              |
| Lung squamous cell carcinoma  | 4  |                              | 3  |                              |
| Small cell lung cancer        | 2  |                              | 0  |                              |
| Other NSCLC                   | 4  |                              | 3  |                              |
| Metastasis                    | 6  |                              | 1  |                              |
| Colorectal cancer             | 2  |                              | 0  |                              |
| Breast cancer                 | 1  |                              | 0  |                              |
| Urothelial cancer             | 2  |                              | 0  |                              |
| Melanoma                      | 1  |                              | 0  |                              |
| Hepatocellular carcinoma      | 0  |                              | 1  |                              |
| Non-malignancy                | 20 |                              | 32 |                              |
| Fungus                        | 4  |                              | 3  |                              |
| Aspergillosis                 | 1  |                              | 2  |                              |
| Cryptococcus                  | 2  |                              | 1  |                              |
| Pneumocystis jiroveci pneumonia | 1 |                              | 0 |                              |
| Mycobacterium tuberculosis    | 2  |                              | 2  |                              |
| Non-tuberculous Mycobacteria  | 1  |                              | 0  |                              |
| Granulomatous inflammation    | 2  | Aspergillosis (n = 1)        | 1  | Mycobacterium tuberculosis (n = 1) |
|                               |    | Non-tuberculous Mycobacteria (n = 1) |   | Candida with tissue culture proved (n = 3) |
|                               |    | Pneumonia with tissue culture proved (n = 6) |   | Mycobacterium tuberculosis with tissue culture proved (n = 2) |
|                               |    | Benign inflammation with clinical follow-up (n = 5) |   | Pneumonia with tissue culture proved (n = 8) |
| Chronic inflammation          | 11 |                              | 26 |                              |
| TBB nondiagnostic             | 19 |                              | 31 |                              |
| No representative samples     | 5  | Lung adenocarcinoma (n = 3)  | 5  | Lung adenocarcinoma (n = 3)  |
|                               |    | Other NSCLC (n = 1)          |    | Benign inflammation (n = 2)  |
| Chronic inflammation          | 5  | Lung adenocarcinoma (n = 5)  | 9  | Lung adenocarcinoma (n = 8)  |
|                               |    | Small cell lung cancer (n = 1) |   | Small cell lung cancer (n = 1) |
| Atypical cell                 | 5  | Lung adenocarcinoma (n = 3)  | 1  | Lung adenocarcinoma (n = 1)  |
|                               |    | Breast cancer (n = 1)        |    | Lung adenocarcinoma (n = 9)  |
|                               |    | Multiple myeloma (n = 1)     |    | Lung squamous cell carcinoma (n = 1) |
|                               |    |                              |    | Hamatoma (n = 1)              |
| Navigation failure            | 4  | Lung adenocarcinoma (n = 2)  | 16 | Mycobacterium tuberculosis (n = 1) |
|                               |    | Benign inflammation (n = 2)  |    | Pneumonia (n = 1)             |
|                               |    |                              |    | Benign inflammation (n = 3)   |

AF = augmented fluoroscopy; CBCT-AF, cone beam computed tomography-derived augmented fluoroscopy; n, number; NSCLC, non-small cell lung cancer; TBB, transbronchial biopsy.
Table 3. Characteristics of EBUS-TBB procedures and target lesions.

| Characteristics                        | Total (n = 236) | CBCT-AF (n = 115) | Non-AF (n = 121) | p-Value |
|----------------------------------------|-----------------|-------------------|------------------|---------|
| Indication (%)                         |                 |                   |                  | 0.100   |
| Initial diagnosis                      | 178 (75.4)      | 82 (71.3)         | 96 (79.3)        |         |
| Re-biopsy                              | 58 (24.6)       | 33 (28.7)         | 25 (20.7)        |         |
| Lesion size (mm, range)                | 27.4 (6.0–64.2) | 24.0 (6.0–62.0)   | 30.6 (6.2–64.2)  | <0.001 *|
| ≤20 mm (%)                             | 88 (37.3)       | 56 (48.7)         | 32 (26.4)        |         |
| Lesion appearance (%)                  |                 |                   |                  | 0.030 * |
| Solid                                  | 193 (81.8)      | 88 (76.5)         | 105 (86.8)       |         |
| Part solid/GGO                        | 43 (18.2)       | 27 (23.5)         | 16 (13.2)        |         |
| Location (%)                           |                 |                   |                  |         |
| Right Upper Lobe                       | 74 (31.4)       | 48 (41.7)         | 26 (21.5)        | 0.001 * |
| Left Upper Lobe (Left Upper Division + |                 |                   |                  |         |
| Lingual)                               | 43 (18.2)       | 16 (13.9)         | 27 (22.3)        |         |
| Lesion size (mm, range)                | 27.4 (6.0–64.2) | 24.0 (6.0–62.0)   | 30.6 (6.2–64.2)  | <0.001 *|
| ≤20 mm (%)                             | 88 (37.3)       | 56 (48.7)         | 32 (26.4)        |         |
| Presence of bronchus sign (%)          |                 |                   |                  | 0.099   |
| Location of probe (%)                  |                 |                   |                  |         |
| Within                                 | 177 (75.0)      | 84 (73.0)         | 93 (76.9)        |         |
| Adjacent to/visible                    | 59 (25.0)       | 31 (27.0)         | 28 (23.1)        |         |
| CXR visible (%)                        |                 |                   |                  |         |
| Total (%)                              | 2/20 (10)       | 2/16 (12.5)       | 0/4 (0)          | 0.632   |
| >10 mm, ≤20 mm                         | 36/68 (52.9)    | 23/40 (57.5)      | 13/28 (46.4)     | 0.257   |
| >20 mm                                 | 132/148 (89.2)  | 55/59 (93.2)      | 77/89 (86.5)     | 0.155   |
| Guide sheath use (%)                   | 124 (52.5)      | 45 (39.1)         | 79 (65.3)        | <0.001 *|
| Duration time (min.)                   | 38.1 (12–109)   | 41.9 (16–109)     | 34.4 (12–78)     | <0.001 *|
| Intraprocedural CBCT use (%)           |                 |                   |                  |         |
| <10 mm                                 | -               | 6/16 (37.5)       | -                |         |
| >10 mm, ≤20 mm                         | -               | 10/40 (25)        | -                |         |
| >20 mm                                 | -               | 3/59 (5.1)        | -                |         |
| Radiation (Gy·cm², range)              |                 |                   |                  |         |
| Total dose                             | -               | 25.48 (9.46–123.41)| -                |         |
| Fluoroscopy dose                       | -               | 2.70 (0.02–10.31) | -                |         |
| Dyna CT dose                           | -               | 22.78 (7.26–119.16)| -                |         |
| Complication (%)                       | 23 (9.7)        | 9 (7.8)           | 14 (11.6)        | 0.227   |
| Bleeding                               | 8 (3.4)         | 5 (4.3)           | 3 (2.5)          | 0.333   |
| Pneumothorax                           | 3 (1.3)         | 0 (0)             | 3 (2.5)          | 0.133   |
| Fever                                  | 12 (5.1)        | 4 (3.5)           | 8 (6.6)          | 0.213   |

AF = augmented fluoroscopy; CBCT-AF = cone beam computed tomography-derived augmented fluoroscopy; CXR = chest X-ray; GGO = ground glass opacity; n = number; * = statistical significance with p-value < 0.05.

Table 4. Comparison of navigation rate and diagnostic yield between the CBCT-AF and non-AF groups.

| Lesion Size | Navigation Success Rate | Diagnostic Yields |
|-------------|-------------------------|-------------------|
|             | CBCT-AF (n = 115)       | Non-AF (n = 121)  | p-Value | CBCT-AF (n = 115) | Non-AF (n = 121) | p Value |
| Total (%)   | 111/115 (96.5)          | 105/121 (86.8)    | 0.006 * | 96/115 (83.5)     | 90/121 (74.4)    | 0.060   |
| ≤10 mm      | 14/16 (87.5)            | 0/4 (0)           | 0.003 * | 11/16 (68.8)      | 0/4 (0)          | 0.026 * |
| >10, ≤20 mm | 38/40 (95)              | 20/28 (71.4)      | 0.009 * | 31/40 (77.5)      | 13/28 (46.4)     | 0.016 * |
| >20 mm      | 59/59 (100)             | 85/89 (95.5)      | 0.127   | 54/59 (91.5)      | 77/89 (86.5)     | 0.254   |

AF = augmented fluoroscopy; CBCT-AF = cone beam computed tomography-derived augmented fluoroscopy; n = number; * = statistical significance with p-value < 0.05.
Table 5. Performance of the diagnosis of PPLs between CBCT-AF and non-AF groups.

|                | CBCT-AF | Non-AF |
|----------------|---------|--------|
|                | Sensitivity | Specificity | PPV  | NPV   | Accuracy |
| CBCT-AF Total  | 82.7     | 100     | 100  | 20.8  | 83.5     |
| ≤10 mm         | 66.7     | 100     | 100  | 16.8  | 68.8     |
| >10, ≤20 mm    | 75.7     | 100     | 100  | 25.0  | 77.5     |
| >20 mm         | 91.4     | 100     | 100  | 16.7  | 91.5     |
| Non-AF Total   | 70.2     | 100     | 100  | 35.4  | 74.4     |
| ≤10 mm         | 0.0      | -       | -    | -     | -        |
| >10, ≤20 mm    | 37.5     | 100     | 100  | 21.1  | 46.4     |
| >20 mm         | 84.2     | 100     | 100  | 52.0  | 86.5     |

AF = augmented fluoroscopy; CBCT-AF = cone beam computed tomography-derived augmented fluoroscopy; NPV = negative predictive value; PPV = positive predictive value.

3.3. Population Excluding Navigation Failure

After excluding 20 procedures (4 in the CBCT-AF group and 16 in the non-AF group) that were navigation failures, the remaining 111 procedures in the CBCT-AF group and 105 procedures in the non-AF group underwent further analysis. The overall diagnostic yield was similar between the 2 groups (86.5% vs. 85.7%, \( p = 0.513 \)). When the target lesion size was 10–20 mm, the diagnostic yield was still not significantly different between the 2 groups (81.6% vs. 65%, \( p = 0.141 \)). The diagnostic yield for other characteristics (indication, lesion appearance, lesion location, bronchus sign, position of the probe, guide sheath use, and final diagnosis with malignancy) was equal between the 2 study populations (Table 6).

Table 6. Comparison of diagnostic yields between the CBCT-AF and non-AF groups after excluding the navigation failure population.

| Variable                                      | CBCT-AF (n = 111) | p-Value | Non-AF (n = 105) | p-Value | p-Value |
|-----------------------------------------------|-------------------|---------|------------------|---------|---------|
| Lesion size (%)                               |                   |         |                  |         |         |
| <10 mm                                        | 73/84 (86.9)      | 0.521   | 83/96 (86.5)     | 0.378   | 0.554   |
| >10, ≤20 mm                                   | 25/27 (85.2)      |         | 7/9 (77.8)       |         | 0.475   |
| >20 mm                                        | 53/61 (86.9)      | 0.554   | 36/44 (81.8)     | 0.245   | 0.328   |
| Indication (%)                                |                   |         |                  |         |         |
| Initial diagnosis                             | 83/95 (87.4)      | 0.370   | 88/103 (85.4)    | 0.734   | 0.426   |
| Re-biopsy                                     | 13/16 (81.3)      |         | 2/2 (100)        |         | 0.686   |
| Lesion appearance on CT (%)                  |                   |         |                  |         |         |
| Solid                                         | 74/84 (88.1)      | 0.282   | 80/92 (86.0)     | 0.540   | 0.428   |
| Part solid/GGO                                | 22/27 (81.5)      |         | 10/12 (83.3)     |         | 0.635   |
| Position                                      |                   |         |                  |         |         |
| Upper lobe                                    | 70/79 (88.6)      | 0.231   | 73/85 (85.9)     | 0.579   | 0.388   |
| Non-upper                                     | 26/32 (81.3)      |         | 17/20 (85)       |         | 0.519   |
| Bronchus sign in CT                           |                   |         |                  |         |         |
| Present                                       | 38/45 (84.4)      | 0.402   | 66/76 (86.8)     | 0.400   | 0.455   |
| Absent                                        | 58/66 (87.9)      |         | 24/29 (82.8)     |         | 0.355   |
| Position of probe                             |                   |         |                  |         |         |
| Within                                        | 76/90 (84.4)      | 0.173   | 58/71 (81.7)     | 0.075   | 0.399   |
| Adjacent to CXR visible                       | 20/21 (95.2)      |         | 32/34 (94.1)     |         | 0.677   |

AF = augmented fluoroscopy; CBCT-AF = cone beam computed tomography-derived augmented fluoroscopy; CT = computed tomography; CXR = chest X-ray; GGO = ground glass opacity; \( n \) = number; * = statistical significance with \( p \)-value < 0.05.
In addition to CBCT-AF use, we found that lesion size might also influence the diagnostic yield of EBUS-TBB in the subgroup analysis. In the CBCT-AF group, large lesions (>20 mm) had a higher EBUS-TBB diagnostic yield than small target lesions (10–20 mm) (91.5% vs. 81.6%, \( p = 0.048 \)). This was also found to be true in the non-AF group (90.6% vs. 65%, \( p < 0.001 \)). No other factor has been detected to affect the diagnostic yield of EBUS-TBB.

4. Discussion

This retrospective study found that the navigation success rate and diagnostic yield were improved when CBCT-AF was performed during EBUS-TBB of lesions \( \leq 20 \) mm. After excluding the procedures that were a failure of navigation, the diagnostic yield showed no difference between the CBCT-AF group and the non-AF group.

TBB has never been a simple procedure for the diagnosis of PPLs. From the technical standpoint, at least three major steps influence the bronchoscopic technique. The first step is demonstrating the capability of reaching a target (navigation). The next step is demonstrating the arrival of the sampling device at the target (confirmation). The final step should be obtaining adequate diagnostic samples (acquisition) [18,19]. Radial-EBUS plays an important role in the “confirmation” step, by verifying contact with the target through its real-time imaging. ROSE provides immediate feedback to ensure proper samples for morphological analysis, thereby implementing the “acquisition” step [8,20]. For the “navigation” step, virtual bronchoscopic navigation or electromagnetic navigation have been considered to be traditional guiding tools in bronchoscopic techniques. Because of the use of static CT imaging, it is impossible to compensate for the motion effect of breathing [21]. Using the navigation system alone for the TBB procedure yields an unacceptable navigation success rate. The use of fluoroscopy has also been attempted to guide TBB [9]. Using real-time imaging, operators can immediately realize the bronchial route through correlation between the target lesion and the tool. Although small or GGO lesions are not easily visible under fluoroscopy [22,23], CBCT-AF could provide the integrated tracking that is derived from 3D CBCT data, which helps the operators easily identify these invisible lesions on the fluoroscopy image. In the present study, CBCT-AF significantly improved the navigation success rate in EBUS-TBB (CBCT-AF vs. non-AF, 96.5% vs. 86.8%, \( p = 0.006 \)). The influence of CBCT-AF on the navigation success rate was significant in the small lesion population (lesion size \( \leq 20 \) mm). CBCT-AF seems to play a navigation role in the EBUS-TBB procedure.

To our knowledge, it was very difficult to diagnose subcentimeter lesions (\( \leq 10 \) mm) via R-EBUS and navigation system. In the present study, the diagnostic yield in the CBCT-AF group was higher than that in the non-AF group when the lesion size was \( \leq 10 \) mm (68.8% vs. 0%, \( p = 0.026 \)). Not only malignancy but also benign disease can be successful diagnosis (Table 7). In the study population with a lesion size of 10–20 mm, the CBCT-AF group also had a better diagnostic yield (77.5% vs. 46.4%, \( p = 0.016 \)). This finding has been reported previously [24]. Pritchett et al., reported that combined electromagnetic navigation and CBCT-AF had a high diagnostic yield for biopsy of PPLs [25]. Casal’s study of 20 consecutive patients found that utilization of intraprocedural CBCT helped improve the diagnostic accuracy of the thin/ultrathin bronchoscope, and radial-EBUS for PPLs [26]. Overall, the use of CBCT significantly improved the bronchoscopic technique in the diagnosis of PPLs.
Table 7. The final diagnosis of 14 subcentimeter lesions that were successful navigation.

| Diagnosis                        | n (%)   |
|----------------------------------|---------|
| Success TBB diagnosis            | 11 (78.6) |
| Malignancy                       | 6 (42.9)  |
| Lung adenocarcinoma              | 4 (28.6)  |
| Colon cancer                     | 1 (7.1)   |
| Urothelial carcinoma             | 1 (7.1)   |
| Non-malignancy                   | 5 (35.7)  |
| Mycobacterium tuberculosis       | 1 (7.1)   |
| Cryptococcus                     | 1 (7.1)   |
| Pneumonia                        | 2 (14.3)  |
| Benign inflammation              | 1 (7.1)   |
| Failure TBB diagnosis            | 3 (21.4)  |
| Lung adenocarcinoma              | 2 (14.3)  |
| Benign inflammation              | 1 (7.1)   |

n = number; TBB = transbronchial biopsy.

There was no difference in the diagnostic yield between the two groups when we omitted the procedures with a failure of navigation. This indicates that the effect of CBCT-AF is eliminated when the factor of navigation is removed. We confirmed that the effect of CBCT-AF in improving the diagnostic yield of EBUS-TBB is mainly due to its assistance in navigating to the target lesion.

Several studies have tried to evaluate the possible navigation benefit of CBCT in performing the bronchoscopic technique [21,26,27]. Most of the studies combined CBCT with virtual bronchoscopic navigation or electromagnetic navigation in their procedures [19,28–30], so it would not be clear whether the benefits were due to CBCT or to the navigation system. Furthermore, few of these studies had a control group. In the present study, we used only CBCT-AF as the navigation tool. In addition to enrolling non-AF patients as our control group, we also included 115 patients in our CBCT-AF group. To our knowledge, this is the largest CBCT-AF study population up to now. We believe our results are convincing and will be helpful in clinical practice.

CBCT-AF has the ability to evaluate “tool-in-lesion” by using real-time 2D imaging. Intraprocedural CBCT offers even better 3D information for confirmation [25,28]. The diagnostic yield in our study was significantly reduced when the target lesion was less than 20 mm in size. Intraprocedural CBCT was attempted more frequently to increase the diagnostic yield in the small lesion population. However, this condition persisted in both groups, even though the study population with a failure of navigation was not included. The cause of this could be the motion effect on the lesion due to respiration [31]. In Chen’s study, the divergence due to the motion effect could be more than 20 mm. The projected target from AF and CBCT imaging can only provide static information. It is very difficult to ensure that the biopsy device is inside the small lesion during breathing activity. CBCT-AF remains unsatisfactory in terms of overcoming the diagnostic impact of small lesion sizes.

The overall diagnostic yield of EBUS-TBB was not significantly different between the CBCT-AF and non-AF groups in all study populations (83.5% vs. 74.4%, p = 0.060). We believe this was because of the components of the study population. There was a large proportion of lesions with a size >20 mm in the non-AF group (73.6%, 89/121). The power of navigation via CBCT-AF was then weakened in this situation.

Studies have found that some factors, such as re-biopsy of post-treated lesions, non-solid lesion appearance on CT, upper lobe location, absence of a bronchus sign, probe adjacent to the lesion, visibility of the lesions on chest plain film, guide sheath use, and final diagnosis of a malignant process might affect the diagnostic yield of EBUS-TBB [5,32–37]. In the present study, there was no significant difference in the diagnostic yield in the subgroup analysis (Table 5). These results are very similar to that of our previous publication [8]. By including ROSE in the procedure, the diagnostic yield of EBUS-TBB was not only improved,
but the effect of the factors mentioned above was reduced. In this situation, the interference of non-homogeneous population in the present study could be decreased.

The duration of the procedure in the CBCT-AF group was longer than that of the non-AF group (41.9 vs. 34.4 min., \( p < 0.001 \)). This is most likely due to the increased time needed for AF and CBCT during the procedure. Of note, the overall complication rate was not elevated in the CBCT-AF group, and the incidence of post-procedure-related fever and bleeding was not statistically higher in the CBCT-AF group than in non-AF group. The three patients that developed pneumothorax after TBB were in non-AF group. We believe the real-time imaging provided by CBCT-AF also helped us avoid injury to the pleura. There was also additional radiation exposure in our study population, which might cause some complications, such as skin injury or risk of cancer [38–40]. In the present study, the mean total radiation dose, Dyna-CT dose, and radiation dose for fluoroscopy were 25.48, 22.78, and 2.70 Gy·cm\(^2\), respectively. The mean estimated dose was 4.1 mSv for total radiation dose, 3.6 mSv for Dyna-CT and 0.4 mSv for fluoroscopy, using a generalized conversion factor of 0.16 mSv/ Gy·cm\(^2\). Very low risk of increasing lifetime fatal malignancy was considered when the exposed radiation dose was lower than 10 mSv [41]. No patient obtained radiation induced dermatitis or skin damage after the procedure in our study population. We believe CBCT-AF was relatively safe, in terms of both procedure-related complications and radiation exposure dose.

All histologic report with “chronic inflammation” has been considered nondiagnostic in some publications [7]. In the present study, positive tissue culture via TBB is an essential criterion for “correctly TBB-proved” in infectious PPLs if no microorganism or only chronic inflammation was revealed in the formal histologic result. When PPLs without specific infection/inflammation process was determined initially, repeat invasive diagnostic methods (repeat bronchoscopy, CT-guided biopsy or surgical resection) would be performed. Only the PPLs decreased in size or disappeared within 6 months follow-up and did not receive special treatment were considered “benign inflammation”, while TBB was considered “true negative”. We believed this definition might be closer to the clinical situation.

Our study has several limitations. First, this was a retrospective study. Some clinical information, such as navigation time, duration of biopsy, and the number of ROSE slides used in each procedure, was not mentioned in the chart review. These factors might also have represented the navigation success rate and diagnostic accuracy of EBUS-TBB in our study. Second, some characters are different between 2 of study population (lesion size, lesion appearance and guide sheath use). The difference could be minimized by using some methods such as propensity score matching. However, the positive findings that are actually meaningful could be missed. For example, only four lesions in non-AF group are smaller than 10 mm. Most small lesion population in CBCT-AF group might also be excluded if propensity score matching was used in our study. Therefore, a prospective randomized study is warranted. Third, fewer benign PPLs were enrolled in our study population (20% in CBCT-AF group and 33.1% in non-AF group). This may cause a lower population of true negative, thereby cause a lower NPV.

Fourth, there was only one operator performing the procedures might hamper the generalizability of the results, but this also eliminates the factors of the learning curve and experience of different operators. Otherwise, our overall diagnostic yield in the CBCT-AF group is very close to that of Pritchett’s and Ali’s publications, which are nearly 90% [19,27,28]. We believe our results are credible and can be applied in clinical practice. Finally, we do not performed brushing and transbronchial needle aspiration for PPLs diagnosis. Previous publications revealed that TBB combing with these techniques have higher sensitivity [42,43], therefore they were performed routinely in many institution. However, histologic specimen is required for immunohistochemical and molecular tests because of the further cancer management but these techniques only offer cytologic specimen. Due to this reason, we do not employ them for our clinical practice. 

All histologic report with “chronic inflammation” has been considered nondiagnostic in some publications [7]. In the present study, positive tissue culture via TBB is an essential criterion for “correctly TBB-proved” in infectious PPLs if no microorganism or only chronic inflammation was revealed in the formal histologic result. When PPLs without specific infection/inflammation process was determined initially, repeat invasive diagnostic methods (repeat bronchoscopy, CT-guided biopsy or surgical resection) would be performed. Only the PPLs decreased in size or disappeared within 6 months follow-up and did not receive special treatment were considered “benign inflammation”, while TBB was considered “true negative”. We believed this definition might be closer to the clinical situation.

Our study has several limitations. First, this was a retrospective study. Some clinical information, such as navigation time, duration of biopsy, and the number of ROSE slides used in each procedure, was not mentioned in the chart review. These factors might also have represented the navigation success rate and diagnostic accuracy of EBUS-TBB in our study. Second, some characters are different between 2 of study population (lesion size, lesion appearance and guide sheath use). The difference could be minimized by using some methods such as propensity score matching. However, the positive findings that are actually meaningful could be missed. For example, only four lesions in non-AF group are smaller than 10 mm. Most small lesion population in CBCT-AF group might also be excluded if propensity score matching was used in our study. Therefore, a prospective randomized study is warranted. Third, fewer benign PPLs were enrolled in our study population (20% in CBCT-AF group and 33.1% in non-AF group). This may cause a lower population of true negative, thereby cause a lower NPV.

Fourth, there was only one operator performing the procedures might hamper the generalizability of the results, but this also eliminates the factors of the learning curve and experience of different operators. Otherwise, our overall diagnostic yield in the CBCT-AF group is very close to that of Pritchett’s and Ali’s publications, which are nearly 90% [19,27,28]. We believe our results are credible and can be applied in clinical practice. Finally, we do not performed brushing and transbronchial needle aspiration for PPLs diagnosis. Previous publications revealed that TBB combing with these techniques have higher sensitivity [42,43], therefore they were performed routinely in many institution. However, histologic specimen is required for immunohistochemical and molecular tests because of the further cancer management but these techniques only offer cytologic specimen. Due to this reason, we do not employ them for our clinical practice.
5. Conclusions

Our study showed that the adoption of CBCT-AF increases the navigation success rate, and thereby facilitates the diagnostic yield of EBUS-TBB for PPLs. CBCT-AF-guided bronchoscopy is associated with an acceptable patient radiation dose and procedure-related complication rate. Due to its safety and accurate navigation, we believe CBCT-AF could be widely applied in bronchoscopic techniques.

Author Contributions: Conceptualization, C.-K.L. and C.-C.H.; methodology, C.-K.L.; software, C.-K.L.; validation, H.-J.F. and Y.-F.W.; formal analysis, C.-K.L. and Z.-H.Y.; investigation, C.-K.L., H.-J.F. and Z.-H.Y.; resources, C.-K.L., H.-J.F., Z.-H.Y., Y.-T.L., Y.-F.W. and S.-G.W.; data curation, C.-K.L. and Y.-F.W.; writing—original draft preparation, C.-K.L.; writing—review and editing, H.-J.F., Z.-H.Y., Y.-T.L., Y.-F.W. and S.-G.W.; visualization, C.-K.L.; supervision, C.-C.H.; project administration, Y.-F.W. and C.-C.H. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the National Taiwan University Cancer Center Institutional Review Board (IRB # 202102061RINC).

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. National Lung Screening Trial Research Team; Aberle, D.R.; Adams, A.M.; Berg, C.D.; Black, W.C.; Clapp, J.D.; Fagerstrom, R.M.; Gareen, I.F.; Gatsonis, C.; Marcus, P.M.; et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N. Engl. J. Med. 2011, 365, 395–409.
2. White, C.S.; Weiner, E.A.; Patel, P.; Britt, E.J. Transbronchial needle aspiration: Guidance with CT fluoroscopy. Chest 2000, 118, 1630–1638. [CrossRef]
3. Hürter, T.; Hanrath, P. Endobronchial sonography: Feasibility and preliminary results. Thorax 1992, 47, 565–567. [CrossRef] [PubMed]
4. Herth, F.J.F.; Ernst, A.; Becker, H.D. Endobronchial ultrasound-guided transbronchial lung biopsy in solitary pulmonary nodules and peripheral lesions. Eur. Respir. J. 2002, 20, 972–974. [CrossRef]
5. Yamada, N.; Yamazaki, K.; Kurimoto, N.; Asahina, H.; Kikuchi, E.; Shinagawa, N.; Oizumi, S.; Nishimura, M. Factors related to diagnostic yield of transbronchial biopsy using endobronchial ultrasonography with a guide sheath in small peripheral pulmonary lesions. Chest 2007, 132, 603–608. [CrossRef]
6. Eberhardt, R.; Anantham, D.; Ernst, A.; Feller-Kopman, D.; Herth, F. Multimodality bronchoscopic diagnosis of peripheral lung lesions: A randomized controlled trial. Am. J. Respir. Crit. Care Med. 2007, 176, 36–41. [CrossRef]
7. Oki, M.; Saka, H.; Ando, M.; Asano, F.; Kurimoto, N.; Morita, K.; Kitagawa, C.; Kogure, Y.; Miyazawa, T. Ultrathin bronchoscopy with multimodal devices for peripheral pulmonary lesions. A randomized trial. Am. J. Respir. Crit. Care Med. 2015, 192, 465–476. [CrossRef]
8. Lin, C.K.; Jan, I.S.; Yu, K.L.; Chang, L.Y.; Fan, H.J.; Wen, Y.F.; Ho, C.C. Rapid on-site cytologic evaluation by pulmonologist improved diagnostic accuracy of endobronchial ultrasound-guided transbronchial biopsy. J. Formos. Med. Assoc. 2020, 119, 1684–1692. [CrossRef]
9. Boonsarnsuk, V.; Raweelert, P.; Juthakarn, S. Endobronchial ultrasound plus fluoroscopy versus fluoroscopy-guided bronchoscopy: A comparison of diagnostic yields in peripheral pulmonary lesions. Lung 2012, 190, 233–237. [CrossRef] [PubMed]
10. Ishida, T.; Asano, F.; Yamazaki, K.; Shinagawa, N.; Oizumi, S.; Moriya, H.; Munakata, M.; Nishimura, M.; Virtual Navigation in Japan Trial Group. Virtual bronchoscopic navigation combined with endobronchial ultrasound to diagnose small peripheral pulmonary lesions: A randomised trial. Thorax 2011, 66, 1072–1077. [CrossRef] [PubMed]
11. Asano, F.; Shinagawa, N.; Ishida, T.; Tsuzuki, A.; Tachihara, M.; Kanazawa, K.; Yamada, N.; Oizumi, S.; Moriya, H. Virtual bronchoscopic navigation improves the diagnostic yield of radial-endobronchial ultrasound for peripheral pulmonary lesions with involved bronchi on CT. Intern. Med. 2015, 54, 1021–1025. [CrossRef]
12. Orth, R.C.; Wallace, M.J.; Kuo, M.D.; Technology Assessment Committee of the Society of Interventional Radiology. C-arm cone-beam CT: General principles and technical considerations for use in interventional radiology. J. Vasc. Interv. Radiol. 2008, 19, 814–820. [CrossRef]
13. Roué, S.; de Latour, B.; Flécher, E.; Guihaine, J.; Castro, M.; Corre, R.; Haigron, P.; Verhoye, J.P. Small pulmonary nodule localization with cone beam computed tomography during video-assisted thoracic surgery: A feasibility study. Interact. Cardiovasc. Thorac. Surg. 2016, 22, 705–711. [CrossRef]
14. Liu, W.P.; Richmon, J.D.; Sorger, J.M.; Azizian, M.; Taylor, R.H. Augmented reality and cone beam CT guidance for transoral robotic surgery. *J. Robot. Surg.* 2015, 9, 223–233. [CrossRef] [PubMed]

15. Weaver, J.J.; Natarajan, N.; Shaw, D.W.W.; Apkon, S.D.; Koo, K.S.H.; Shivaram, G.M.; Eric, J.; Monroe, E.J. Transforaminal intrathoracic delivery of nusinersen using cone-beam computed tomography for children with spinal muscular atrophy and extensive surgical instrumentation: Early results of technical success and safety. *Pediatr. Radiol.* 2018, 48, 392–397. [CrossRef] [PubMed]

16. Kenngott, H.G.; Wagner, M.; Gondan, M.; Nickel, F.; Nolden, M.; Fetzer, A.; Weitz, J.; Fischer, L.; Speidel, S.; Meinzner, H.P.; et al. Real-time image guidance in laparoscopic liver surgery: First clinical experience with a guidance system based on intraoperative CT imaging. *Surg. Endosc.* 2014, 28, 933–940. [CrossRef] [PubMed]

17. Yang, S.M.; Yu, K.L.; Lin, K.H.; Liu, Y.L.; Sun, S.E.; Meng, L.H.; Ko, H.J. Real-time augmented fluoroscopy-guided lung marking for thorascopic resection of small pulmonary nodules. *Surg. Endosc.* 2020, 34, 477–484. [CrossRef]

18. Casal, R.F. Cone Beam CT-Guided Bronchoscopy: Here to Stay? *J. Bronchol. Interv. Pulmonol.* 2018, 25, 255–256. [CrossRef]

19. Pritchett, M.A.; Schampaert, S. Tipping Point: Cone Beam CT with Augmented Fluoroscopy for the Biopsy and Treatment of Peripheral Nodules. *J. Bronchol. Interv. Pulmonol.* 2019, 26, e13–e15. [CrossRef]

20. Da Cunha Santos, G.; Ko, H.M.; Saieg, M.A.; Geddie, W.R. “The petals and thorns” of ROSE (rapid on-site evaluation). *Cancer Cytopathol.* 2013, 121, 4–8. [CrossRef]

21. Verhoeven, R.L.J.; Fütterer, J.J.; Hoefsloot, W.; van der Heijden, E.H.F.M. Cone-Beam CT Image Guidance with and without Electromagnetic Navigation Bronchoscopy for Biopsy of Peripheral Pulmonary Lesions. *J. Bronchol. Interv. Pulmonol.* 2021, 28, 60–69. [CrossRef] [PubMed]

22. Stringfield, J.T.; Markowizt, D.J.; Bentz, R.R.; Welch, M.H.; Weg, J.G. The effect of tumor size and location on diagnosis by fiberoptic bronchoscopy. *Chest* 1977, 71, 474–476. [CrossRef] [PubMed]

23. Yang, S.M.; Yu, K.L.; Lin, K.H.; Liu, Y.L.; Sun, S.E.; Meng, L.H.; Ko, H.J. Localization of Small Pulmonary Nodules Using Augmented Fluoroscopic Bronchoscopy: Experience from 100 Consecutive Cases. *World J. Surg.* 2020, 44, 2418–2425. [CrossRef] [PubMed]

24. Casal, R.F.; Sarkiss, M.; Jones, A.K.; Stewart, J.; Tam, A.; Grosu, H.B.; Ost, D.E.; Jimenez, C.A.; Eapen, G.A. Cone beam computed tomography-guided thin/ultrathin bronchoscopy for diagnosis of peripheral lung nodules: A prospective pilot study. *J. Thorac. Dis.* 2018, 10, 6690–6699. [CrossRef] [PubMed]

25. Kheir, F.; Thakore, S.R.; Becerra, J.P.U.; Tahboub, M.; Kamat, R.; Abdelghani, R.; Fernandez-Bussy, S.; Kaphle, U.R.; Majid, A. Cone-Beam Computed Tomography-Guided Electromagnetic Navigation for Peripheral Lung Nodules. *Respiration* 2021, 100, 44–51. [CrossRef] [PubMed]

26. Kheir, F.; Thakore, S.R.; Becerra, J.P.U.; Tahboub, M.; Kamat, R.; Abdelghani, R.; Fernandez-Bussy, S.; Kaphle, U.R.; Majid, A. Cone-Beam Computed Tomography-Guided Electromagnetic Navigation for Peripheral Lung Nodules. *Respiration* 2021, 100, 44–51. [CrossRef] [PubMed]

27. Pritchett, M.A.; Schampaert, S.; de Groot, J.A.H.; Schirmer, C.C.; van der Bom, I. Cone-Beam CT with Augmented Fluoroscopy Combined with Electromagnetic Navigation Bronchoscopy for Biopsy of Peripheral Pulmonary Nodules. *J. Bronchol. Interv. Pulmonol.* 2018, 25, 274–282. [CrossRef]

28. Casal, R.F.; Sarkiss, M.; Jones, A.K.; Stewart, J.; Tam, A.; Grosu, H.B.; Ost, D.E.; Jimenez, C.A.; Eapen, G.A. Cone beam computed tomography-guided thin/ultrathin bronchoscopy for diagnosis of peripheral lung nodules: A prospective pilot study. *J. Thorac. Dis.* 2018, 10, 6690–6699. [CrossRef] [PubMed]

29. Cheng, G.Z.; Liu, L.; Nobari, M.; Miller, R.; Wahidi, M. Cone beam navigation bronchoscopy: The next frontier. *J. Thorac. Dis.* 2020, 12, 3272–3278. [CrossRef] [PubMed]

30. Ali, E.A.A.; Takizawa, H.; Kawakita, N.; Sawada, T.; Tsuibo, M.; Toba, H.; Takashima, M.; Matsumoto, D.; Yoshida, M.; Kawakami, Y.; et al. Transbronchial Biopsy Using an Ultrathin Bronchoscope Guided by Cone-Beam Computed Tomography and Virtual Bronchoscopic Navigation in the Diagnosis of Pulmonary Nodules. *Respiration* 2019, 98, 321–328. [CrossRef]

31. Sobieszczyk, M.J.; Yuan, Z.; Li, W.; Krimsky, W. Biopsy of peripheral lung nodules utilizing cone beam computer tomography with and without trans bronchial access tool: A retrospective analysis. *J. Thorac. Dis.* 2018, 10, 5953–5959. [CrossRef]

32. Bowling, M.R.; Brown, C.; Anciano, C.J. Feasibility and Safety of the Transbronchial Access Tool for Peripheral Pulmonary Nodule and Mass. *Ann. Thorac. Surg.* 2017, 104, 443–449. [CrossRef] [PubMed]

33. Chen, A.; Pastis, N.; Furukawa, B.; Silvestri, G.A. The effect of respiratory motion on pulmonary nodule location during electromagnetic navigation bronchoscopy. *Chest* 2015, 147, 1275–1281. [CrossRef] [PubMed]

34. Liao, B.C.; Bai, Y.Y.; Lee, J.H.; Lin, C.C.; Lin, S.Y.; Lee, Y.F.; Ho, C.C.; Shih, J.Y.; Chang, Y.C.; Yu, C.J.; et al. Outcomes of research biopsies in clinical trials of EGR mutation-positive non-small cell lung cancer patients pretreated with EGRF-tyrosine kinase inhibitors. *J. Formos. Assoc.* 2018, 117, 326–331. [CrossRef] [PubMed]

35. Izumo, T.; Matsumoto, Y.; Chavez, C.; Tsuchida, T. Re-biopsy by endobronchial ultrasound procedures for mutation analysis of non-small cell lung cancer after EGFR tyrosine kinase inhibitor treatment. *BMC Pulm. Med.* 2016, 16, 106. [CrossRef] [PubMed]

36. Herth, F.J.; Annema, J.T.; Eberhardt, R.; Yasufuku, K.; Ernst, A.; Krasnik, M.; Rintoul, R.C. Endobronchial ultrasound with transbronchial needle aspiration for restaging the mediastinum in lung cancer. *J. Clin. Oncol.* 2008, 26, 3346–3450. [CrossRef]

37. Kurimoto, N.; Miyazawa, T.; Okimasa, S.; Maeda, A.; Oiwa, H.; Miyazu, Y.; Murayama, M. Endobronchial ultrasonography using a guide sheath increases the ability to diagnose peripheral pulmonary lesions endoscopically. *Chest* 2004, 126, 959–965. [CrossRef] [PubMed]

38. Otterburn, D.; Lesken, A. Iatrogenic fluoroscopy injury to the skin. *Ann. Plast. Surg.* 2010, 65, 462–465. [CrossRef]
39. Timins, J.K.; Lipoti, J.A. Radiation risks of high-dose fluoroscopy. *N. J. Med.* **2000**, *97*, 31–34.

40. Kovoor, P.; Ricciardello, M.; Collins, L.; Uther, J.B.; Ross, D.L. Risk to patients from radiation associated with radiofrequency ablation for supraventricular tachycardia. *Circulation* **1998**, *98*, 1534–1540. [CrossRef]

41. Picano, E.; Piccaluga, E.; Padovani, R.; Antonio Traino, C.; Grazia Andreassi, M.; Guagliumi, G. Risks Related To Fluoroscopy Radiation Associated with Electrophysiology Procedures. *J. Atr. Fibrillation* **2014**, *31*, 7–1044.

42. Kovnat, D.M.; Rath, G.S.; Anderson, W.M.; Siber, F.; Snider, G.L. Bronchial brushing through the flexible fiberoptic bronchoscope in the diagnosis of peripheral pulmonary lesions. *Chest* **1975**, *67*, 179–184. [CrossRef] [PubMed]

43. Mondon, M.; Sotgiu, G.; Bonifazi, M.; Dore, S.; Parazzini, E.M.; Carlucci, P.; Gasparini, S.; Centanni, S. Transbronchial needle aspiration in peripheral pulmonary lesions: A systematic review and meta-analysis. *Eur. Respir. J.* **2016**, *48*, 196–204. [CrossRef] [PubMed]